DUBLIN–(BUSINESS WIRE)–Feb 19, 2021–
The "AXL Kinase inhibitor – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering.
This "AXL Kinase inhibitor – Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence AXL Kinase inhibitor R&D. The therapies under development are focused on novel approaches for AXL Kinase inhibitor.
AXL Kinase inhibitor Emerging Drugs Chapters
This segment of the AXL Kinase inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
AXL Kinase inhibitor Emerging Drugs
- Bemcentinib: BerGenBio / Rigel Pharmaceuticals
Bemcentinib (BGB324) is a potent, selective and orally bioavailable AXL inhibitor and a potential future cornerstone to therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection. The drug is in phase II program, focused on establishing proof of concept that bemcentinib may reverse and prevent resistance to immune, targeted and chemotherapy.
- Sitravatinib: Mirati Therapeutics
Sitravatinib is an oral, potent, spectrum-selective RTK inhibitor. It inhibits several closely related RTKs, including the TAM family (TYRO3, AXL and MER), VEGFR2 and KIT. This inhibition weakens the cancer’s defenses in the tumor microenvironment.
AXL Kinase inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different AXL Kinase inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on AXL Kinase inhibitor
There are approx. 15+ key companies which are developing the AXL Kinase inhibitor. The companies which have their AXL Kinase inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Mirati Therapeutics.
The report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
AXL Kinase inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
AXL Kinase inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses AXL Kinase inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AXL Kinase inhibitor drugs.
AXL Kinase inhibitor Report Insights
- AXL Kinase inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
AXL Kinase inhibitor Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Scenario and Emerging Therapies:
- How many companies are developing AXL Kinase inhibitor drugs?
- How many AXL Kinase inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for AXL Kinase inhibitor?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the AXL Kinase inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for AXL Kinase inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- BerGenBio
- Rigel Pharmaceuticals
- Mirati Therapeutics
- Ipsen
- SignalChem Lifesciences
- Arcus Biosciences
- Symphogen
- Qurient Co
- Daiichi Sankyo Company
- Aravive
- Exelixis
Key Products
- Bemcentinib
- Sitravatinib
- Cabozantinib
- Research programme: TAM inhibitors
- Research programme: AXL receptor tyrosine kinase inhibitors
- Sym 028
- Q-702
- AB 329
- Aravive S6
- XL092
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ti83ou
View source version on businesswire.com:https://www.businesswire.com/news/home/20210219005221/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/19/2021 05:50 AM/DISC: 02/19/2021 05:50 AM
http://www.businesswire.com/news/home/20210219005221/en
